Drug intelligence / Profile preview

HCP-20A

Development stage: Unknown
Lead developer: Healthcare Product Development
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Topical

Overview

HCP-20A is a topical cream formulation developed by Healthcare Product Development for the treatment of atopic dermatitis (atopic eczema). It is a botanical-based product containing a combination of anti-inflammatory and antibacterial agents, with *Boswellia serrata* extract as a primary active component. *Boswellia serrata* contains boswellic acids that act as inhibitors of 5-lipoxygenase (5-LOX), an enzyme involved in the production of pro-inflammatory leukotrienes. The drug has been evaluated in a Phase 2 pilot study in the United Kingdom to assess its safety and clinical efficacy in patients with atopic eczema.

Targets

ALOX5 (Arachidonate 5-lipoxygenase)

Beyond the preview

Go deeper on HCP-20A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCP-20A.

Explore the full profile